Liraglutide (Saxenda®) for the treatment of obesity: a commentary on NICE Technology Appraisal 664


  • Hassan Kahal Bristol
  • Kamrudeen Mohammed
  • Kathryn Lonnen
  • Thozhukat Sathyapalan
  • Chris Walton



Saxenda, obesity, Weight Management Service, NICE TA664


Saxenda, Liraglutide 3.0 mg, is a glucagon-like peptide-1 (GLP-1) analogue that is licensed for the treatment of adults with overweight and obesity. In this commentary we review the NICE technology appraisal (TA664) on the use of Saxenda in the National Health Service (NHS) and its implication in clinical practice.

Author Biography

Hassan Kahal, Bristol

Consultant in Diabetes and Endocrinology in Bristol 


National Institute for Health and Care Excellence (NICE). Liraglutide for managing overweight and obesity. [TA664]. 9 December 2020. (Accessed 5 Feb 2021).

Tahrani, Parretti, O’Kane, Chowhan, Ratcliffe, Le Brocq. Managing obesity in primary care.

British Obesity and Metabolic Surgery Society. Commissioning guide: Weight assessment and management clinics (tier 3). 2014.

All-Party Parliamentary Group on Obesity. The current landscape of obesity services: a report from the All-Party Parliamentary Group on Obesity. [Accessed 16 Feb 2021].

EMC. Saxenda 6 mg/mL solution for injection in pre-filled pen. [Accessed 5 Feb 2021].

Pi-Sunyer X, Astrup A, Fujioka K, et al, SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373(1):11–22.

National Institute for Health and Care Management. Obesity management in adults. [Accessed 5 Feb 2021].

World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF Consultation. 2006. Geneva: World Health Organization.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl1):S62–S69.

Wilding JPH, Batterham RL, Calanna S, et al, for the STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384(11):989–1002.

Davies M, Færch L, Jeppesen OK, et al, STEP Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397(10278):971–84.

Papamargaritis D, Al-Najim W, Lim J, et al. Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. BMJ Open 2020;10(2):e034137.







Most read articles by the same author(s)